Decreased expression of mitochondrial aminoacyl-tRNA synthetases causes downregulation of mitochondrial OXPHOS subunits in type 2 diabetic skeletal muscle

Iliana López-Soldado; Adrian Gabriel Torres; Raúl Ventura; Inma Martínez-Ruiz; Angels Díaz-Ramos; Evarist Planet; Diane Cooper; Agnieszka Pazderska; Krzysztof Wanic; Declan O’Hanlon; Donal J. O’Gorman; Teresa Carbonell; Lluís Ribas de Pouplana; John J. Nolan; María Isabel Hernández-Alvarez

doi:10.1101/2022.12.30.22283970

Abstract

Type 2 diabetes mellitus (T2D) affects millions of people worldwide and is one of the leading causes of morbidity and mortality. The skeletal muscle (SKM) is the most important tissue involved in maintaining glucose homeostasis and substrate oxidation, and it undergoes insulin resistance in T2D. In this study, we identify the existence of alterations in the expression of mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) in skeletal muscle from two different forms of T2D: early-onset type 2 diabetes (YT2) (onset of the disease before 30 years of age) and the classical form of the disease (OT2). GSEA analysis from microarray studies revealed the repression of mitochondrial mt-aaRSs independently of age, which was validated by real-time PCR assays. In agreement with this, a reduced expression of several encoding mt-aaRSs was also detected in skeletal muscle from diabetic (db/db) mice but not in obese ob/ob mice. In addition, the expression of the mt-aaRSs proteins most relevant in the synthesis of mitochondrial proteins, threonyl-tRNA, and leucyl-tRNA synthetases (LARS2 and TARS2) were also repressed in muscle from db/db mice. It is likely that these alterations participate in the reduced expression of proteins synthesized in the mitochondria detected in db/db mice. Because it is known that, nitrosative stress inhibits aminoacylation of TARS2 and LARS2 activities, we noticed an increased protein expression of iNOS in isolated muscle mitochondria in diabetic mice.

Our results indicate a reduced expression of mitochondrial mt-aaRSs in skeletal muscle from T2D patients, which may participate in the reduced expression of proteins synthesized in mitochondria. This may be due to an enhanced NO production secondary to enhanced iNOS expression in muscle under diabetic conditions.

Highlights

Mt-aaRSs are downregulated in the skeletal muscle of type 2 diabetic patients and diabetic mice.
The downregulation of mt-aaRSs in the skeletal muscle of diabetic mice is affecting the synthesis of ND2 which is a mitochondrially encoded subunit of complex I.
Mitochondrial iNOS could be a target for reduced expression of mt-aaRSs in the skeletal muscle of diabetic mice.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The project was funded with a grant to JJN at Trinity College Dublin from EFSD/Novo Nordisk Clinical Research Program in Adolescents with Type 2 Diabetes (Cellular Mechanisms of Insulin Resistance in Early Onset Type 2 Diabetes, grant reference T04001), Grant 2017SGR1015 from the Generalitat de Catalunya, CIBERDEM (Instituto de Salud Carlos III), MICINN (PID2019-105466RA-I00 AEI/ 10.13039/501100011033, RYC2018-024345-I MCIN/AEI/ 10.13039/501100011033, and PID2019-106209RB-I00 AEI/ 10.13039/501100011033), la Caixa Foundation, Health Research Grant 2021 (LCF/PR/HR21/52410007), Fundacion BBVA, EFSD, and AFM Telethon. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO (Government of Spain).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The project was approved by the Joint St James Hospital and Adelaide and Meath Hospital Ethics Committee, with a reference number of 2008/06/03.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes